Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2023 financial results after the U.S. financial markets close on Thursday, May 4, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial results.
Related news for (ONCT)
- oncternal therapeutics announces updated safety and efficacy data for phase 1/2 study of onct-534 for the treatment of r/r metastatic castration-resistant prostate cancer
- Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- Oncternal Therapeutics Announces Reverse Stock Split